Silexion Therapeutics Corp
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| 2025 | 2024 | |
|---|---|---|
| OPERATING EXPENSES: | ||
| Research and development (including $0 and $1,796 from related party, for the year ended December 31, 2025 and December 31, 2024, respectively) | $7,140 | $5,815 |
| General and administrative (including $134 and $2,972 from related party, for the years ended December 31, 2025 and December 31, 2024, respectively) | 4,492 | 6,756 |
| TOTAL OPERATING EXPENSES | 11,632 | 12,571 |
| OPERATING LOSS | 11,632 | 12,571 |
| Financial expenses (income), net (including $232 and $(1,249) from related party, for the years ended December 31, 2025 and December 31, 2024, respectively) | 277 | 3,938 |
| LOSS BEFORE INCOME TAX | $11,909 | $16,509 |
| INCOME TAX | 3 | 10 |
| NET LOSS FOR THE YEAR | $11,912 | $16,519 |
| Attributable to: | ||
| Equity holders of the Company | 11,912 | 16,443 |
| Non-controlling interests | - | 76 |
| $11,912 | $16,519 | |
| LOSS PER ORDINARY SHARE, BASIC AND DILUTED* | $8.96 | $394.94 |
|---|---|---|
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE*: | 1,329,515 | 41,635 |
- All share amounts have been retroactively adjusted to reflect a 1-for-15 reverse share splits as discussed in Note 1(e)
F - 5
CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS’ EQUITY (CAPITAL DEFICIENCY)
(U.S. dollars in thousands, except per share data)
| Redeemable Convertible Preferred Shares*** · Ordinary shares*** · Additionalpaid-in Capital · Accumulated deficit · Total shareholders' equity (capital deficiency) · Total redeemable convertible preferred shares and contingently redeemable non-controlling interests and shareholders' equity (capital deficiency) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A preferred shares · Series A-1 preferred shares · Series A-2 preferred shares · Series A-3 preferred shares · Series A-4 preferred shares · Contingently redeemable non-controlling interests | ||||||||||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Amount · Shares · Amount | ||||||||||||||||||
| BALANCE AT JANUARY 1, 2024 | 2,875 | $7,307 | 676 | $2,392 | 337 | $2,264 | 470 | $2,683 | 161 | $411 | $3,420 | 6,516 | * | $11,335 | $(26,811) | $(15,476) | $3,001 | |
| CHANGES DURING 2024: | ||||||||||||||||||
| Exercise of pre-funded options | 919 | ** | * | * | * | * | ||||||||||||
| Share-based compensation | 5,242 | * | 5,862 | 5,862 | 5,862 | |||||||||||||
| Issuance of convertible preferred shares upon net exercise of warrants | 10 | - | 62 | $334 | - | - | - | - | 334 | |||||||||
| Net loss | (76) | (16,443) | (16,443) | (16,519) | ||||||||||||||
| Conversion of convertible preferred shares and noncontrolling interests upon the effectiveness of the SPAC Merger (see Note 1(d)) | (2,875) | $(7,307) | (686) | $(2,392) | (337) | $(2,264) | (470) | $(2,683) | (223) | $(745) | $(3,344) | 31,873 | 1 | 18,734 | 18,735 | - | ||
| Issuance of ordinary shares upon Transactions (see Note 1(d)) | 27,825 | * | * | * | ||||||||||||||
| Issuance of ordinary shares for ELOC holders, see Note 3(d) | 50,915 | 1 | 3,332 | 3,333 | 3,333 | |||||||||||||
| BALANCE AT DECEMBER 31, 2024 | -,- | -,- | -,- | -,- | -,- | -,- | -,- | -,- | -,- | -,- | -,- | 123,290 | **** | $2 | $39,263 | $(43,254) | $(3,989) | $(3,989) |
| CHANGES DURING 2025: | ||||||||||||||||||
| Exercise of pre-funded options | 9 | * | * | * | * | |||||||||||||
| Issuance of ordinary shares and warrants upon January 2025 and September 2025 public offerings, net of issuance costs and exercise of pre-funded warrants to ordinary shares (see Note 8(a)) | 1,746,914 | 23 | 9,427 | 9,450 | 9,450 | |||||||||||||
| Exercise of warrants, January 2025 and September 2025 (see Note 8(a)) | 487,683 | 7 | 2,637 | 2,644 | 2,644 | |||||||||||||
| Issuance of ordinary shares and warrants upon warrants inducement transactions, January 2025 and August 2025, net of issuance costs (see Note 8(b)) | 300,208 | 4 | 4,292 | 4,296 | 4,296 | |||||||||||||
| Share-based compensation | 28 | * | 134 | 134 | 134 | |||||||||||||
| Conversion of Underwriters Promissory Note (see Note 3(a)) | 18,519 | * | 356 | 356 | 356 | |||||||||||||
| Conversion of Sponsor Promissory Note (see Note 3(b)) | 450,000 | 6 | 1,618 | 1,624 | 1,624 | |||||||||||||
| Net loss | (11,912) | (11,912) | (11,912) | |||||||||||||||
| BALANCE AT DECEMBER 31, 2025 | -,- | -,- | -,- | -,- | -,- | -,- | -,- | -,- | -,- | -,- | -,- | 3,126,651 | $42 | $57,727 | $(55,166) | $2,603 | $2,603 | |
** Represents exercises of fully vested pre-funded options for the Company’s ordinary shares at an exercise price of $0.339 or 0.339 NIS per share
*** All share amounts have been adjusted (in the case of prior periods, retroactively) to reflect the 1-for-9 and 1-for-15 reverse share splits effected in November 2024 and July 2025, respectively, as discussed in Note 1(e)
**** Net of 28 treasury shares held by the Company as of December 31, 2024
F - 6
CONSOLIDATED STATEMENTS OF CASH FLOWS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.